Altimmune names Richard Menziuso as principal accounting officer
The appointment, effective September 29, 2026, keeps Gregory Weaver as chief financial officer.
SEC filing
Latest
4 stories
Tuesday, September 29
Monday, August 31
Altimmune registers Phase 3 pemvidutide trial in MASH under "PERFORMA" name
Friday, August 14
NewAmsterdam Pharma names new accounting officer, details COO exit terms
The company appointed Robert W. Gunning as principal accounting officer while finalizing separation and advisory terms for former COO Douglas Kling.
SEC filing (2)
Wednesday, August 12
Altimmune reports Q2 2026 results as pemvidutide advances in MASH, AUD and ALD
The company started its Phase 3 MASH trial, posted positive Phase 2 alcohol use disorder data, finished enrollment in a liver disease trial and held $519 million in cash and investments.
SEC filing